Tokyo Tape
Sign in
← ASKA Pharmaceutical Holdings

Quarterly report · Q3

4886.TEDINET S100SSGE
Period2023-04-01 → 2023-12-31
Filed2024-02-09
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥48.8bn2023-04-01 → 2023-12-31Cons.Net sales
Revenue¥60.5bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥47.3bn2022-04-01 → 2022-12-31Cons.Net sales
Operating income¥5.5bn2023-04-01 → 2023-12-31Cons.Operating income
Operating income¥5.0bn2022-04-01 → 2022-12-31Cons.Operating income
Ordinary income¥5.6bn2023-04-01 → 2023-12-31Cons.Ordinary income
Ordinary income¥5.2bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥5.2bn2022-04-01 → 2022-12-31Cons.Ordinary income
Profit before tax¥8.5bn2023-04-01 → 2023-12-31Cons.Income before income taxes
Profit before tax¥5.4bn2022-04-01 → 2022-12-31Cons.Income before income taxes
Net income (owners)¥6.5bn2023-04-01 → 2023-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.2bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥4.2bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income¥6.5bn2023-04-01 → 2023-12-31Cons.Profit loss
Net income¥4.2bn2022-04-01 → 2022-12-31Cons.Profit loss
Total assets¥94.9bnat 2023-12-31Cons.Assets
Total assets¥87.1bnat 2023-03-31Cons.Assets
Total assets¥90.8bnat 2022-12-31Cons.Total assets (5-year summary)
Total liabilities¥34.5bnat 2023-12-31Cons.Liabilities
Total liabilities¥32.6bnat 2023-03-31Cons.Liabilities
Net assets / equity¥60.4bnat 2023-12-31Cons.Net assets
Net assets / equity¥54.5bnat 2023-03-31Cons.Net assets
Net assets / equity¥54.1bnat 2022-12-31Cons.Net assets (5-year summary)
Cash and deposits¥17.5bnat 2023-12-31Cons.Cash and deposits
Cash and deposits¥14.5bnat 2023-03-31Cons.Cash and deposits
EPS (basic)¥228.132023-04-01 → 2023-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥82.192023-10-01 → 2023-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥150.082022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥148.192022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥64.972022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio63.7%at 2023-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio62.6%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio59.6%at 2022-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 34
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-04-01 → 2023-12-31¥166m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-04-01 → 2023-12-31¥124m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-04-01 → 2023-12-31¥41m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-04-01 → 2023-12-31−¥103m
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-12-31−¥41m
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-12-31−¥41m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-12-31−¥903m
jpcrp040300-q3r_E35791-000Animal Health Businessreportable segmentrevenue2023-04-01 → 2023-12-31¥5.1bn
jpcrp040300-q3r_E35791-000Animal Health Businessreportable segmentrevenue external2023-04-01 → 2023-12-31¥5.1bn
jpcrp040300-q3r_E35791-000Animal Health Businessreportable segmentsegment profit2023-04-01 → 2023-12-31¥186m
jpcrp040300-q3r_E35791-000Pharmaceutical Businessreportable segmentrevenue2023-04-01 → 2023-12-31¥43.6bn
jpcrp040300-q3r_E35791-000Pharmaceutical Businessreportable segmentrevenue external2023-04-01 → 2023-12-31¥43.6bn
jpcrp040300-q3r_E35791-000Pharmaceutical Businessreportable segmentsegment profit2023-04-01 → 2023-12-31¥6.3bn
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-12-31¥48.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-12-31¥48.8bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-12-31¥41m
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-12-31¥6.4bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-12-31¥196m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-12-31¥155m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-12-31¥41m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-12-31−¥26m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥41m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥41m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥767m
jpcrp040300-q3r_E35791-000Animal Health Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥5.2bn
jpcrp040300-q3r_E35791-000Animal Health Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥5.2bn
jpcrp040300-q3r_E35791-000Animal Health Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥417m
jpcrp040300-q3r_E35791-000Pharmaceutical Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥41.9bn
jpcrp040300-q3r_E35791-000Pharmaceutical Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥41.9bn
jpcrp040300-q3r_E35791-000Pharmaceutical Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥5.4bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-12-31¥47.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-12-31¥47.3bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-12-31¥41m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-12-31¥5.8bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 328
ItemContextValueUnit
Non operating incomePrior1YTDDuration402000000JPY
Non operating incomeCurrentYTDDuration378000000JPY
Interest expenses noePrior1YTDDuration38000000JPY
Interest expenses noeCurrentYTDDuration31000000JPY
Expenses of inactive non current assets noePrior1YTDDuration40000000JPY
Expenses of inactive non current assets noeCurrentYTDDuration72000000JPY
Other noePrior1YTDDuration118000000JPY
Other noeCurrentYTDDuration169000000JPY
Non operating expensesPrior1YTDDuration197000000JPY
Non operating expensesCurrentYTDDuration273000000JPY
Ordinary incomePrior1YTDDuration5246000000JPY
Ordinary incomeCurrentYTDDuration5631000000JPY
Gain on sales of investment securities eiPrior1YTDDuration121000000JPY
Gain on sales of investment securities eiCurrentYTDDuration2889000000JPY
Extraordinary incomePrior1YTDDuration121000000JPY
Extraordinary incomeCurrentYTDDuration2889000000JPY
Income before income taxesPrior1YTDDuration5367000000JPY
Income before income taxesCurrentYTDDuration8520000000JPY
Income taxes currentPrior1YTDDuration1036000000JPY
Income taxes currentCurrentYTDDuration2151000000JPY
Income taxes deferredPrior1YTDDuration148000000JPY
Income taxes deferredCurrentYTDDuration-88000000JPY
Income taxesPrior1YTDDuration1184000000JPY
Income taxesCurrentYTDDuration2062000000JPY
Profit lossPrior1YTDDuration4183000000JPY
Profit lossCurrentYTDDuration6458000000JPY
Profit loss attributable to owners of parentPrior1YTDDuration4183000000JPY
Profit loss attributable to owners of parentCurrentYTDDuration6458000000JPY
Profit lossPrior1YTDDuration4183000000JPY
Profit lossCurrentYTDDuration6458000000JPY
Valuation difference on available for sale securities net of tax ociPrior1YTDDuration858000000JPY
Valuation difference on available for sale securities net of tax ociCurrentYTDDuration-131000000JPY
Remeasurements of defined benefit plans net of tax ociPrior1YTDDuration20000000JPY
Remeasurements of defined benefit plans net of tax ociCurrentYTDDuration-23000000JPY
Share of other comprehensive income of associates accounted for using equity method ociPrior1YTDDuration477000000JPY
Share of other comprehensive income of associates accounted for using equity method ociCurrentYTDDuration285000000JPY
Other comprehensive incomePrior1YTDDuration1355000000JPY
Other comprehensive incomeCurrentYTDDuration130000000JPY
Comprehensive incomePrior1YTDDuration5538000000JPY
Comprehensive incomeCurrentYTDDuration6588000000JPY
Comprehensive income attributable to owners of the parentPrior1YTDDuration5538000000JPY
Comprehensive income attributable to owners of the parentCurrentYTDDuration6588000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q3r_E35791-000PharmaceuticalBusinessReportableSegmentsMember41916000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q3r_E35791-000AnimalHealthBusinessReportableSegmentsMember5187000000JPY
Revenues from external customersPrior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember155000000JPY
Revenues from external customersPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember47259000000JPY
Revenues from external customersPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersPrior1YTDDuration47259000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q3r_E35791-000PharmaceuticalBusinessReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q3r_E35791-000AnimalHealthBusinessReportableSegmentsMember－JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2023-04-01/2023-12-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass